Skip to main content

Table 3 Means (and 95% CI:s) of quality of life and mental health rating scores for subjects who completed the study.

From: Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: A double-blind randomised placebo controlled 6-month trial

  Placebo (n = 14) Paroxetine (n = 23) Placebo-Paroxetine  
  Mean (95% CI) Mean (95% CI) Mean difference (95% CI) p
SF-36     
   Baseline 51.2 (42.6 to 59.8) 56.2 (48.6 to 63.7) -4.7 (-16.3 to 6.4) 0.381
   3 months 59.1 (51.2 to 67.0) 70.1 (63.4 to 76.7) -11.0 (-21.4 to -0.6) 0.039
   6 months 56.9 (47.5 to 66.2) 65.8 (58.5 to 73.6) -8.9 (-20.8 to 2.9) 0.135
HADS total score     
   Baseline 15.8 (12.5 to 19.1) 14.0 (11.7 to 16.2) 1.8 (-1.9 to 5.6) 0.327
   3 months 11.2 (9.0 to 13.5) 8.5 (6.6 to 10.4) 2.8 (-0.2 to 5.7) 0.066
   6 months 12.1 (8.9 to 15.4) 10.2 (7.6 to 12.7) 1.9 (-2.2 to 6.1) 0.351
HADS depression score     
   Baseline 8.2 (6.2 to 10.2) 7.3 (5.8 to 8.7) 0.9 (-1.4 to 3.4) 0.416
   3 months 5.1 (3.8 to 6.3) 3.8 (2.7 to 4.9) 1.3 (-0.4 to 2.9) 0.129
   6 months 6.2 (4.6 to 7.7) 5.5 (4.3 to 6.6) 0.7 (-1.2 to 2.7) 0.448
HADS anxiety score     
   Baseline 7.6 (5.8 to 9.4) 6.7 (5.6 to 7.8) 0.9 (-1.1 to 2.8) 0.366
   3 months 6.2 (4.8 to 7.6) 4.6 (3.5 to 5.8) 1.6 (-0.2 to 3.4) 0.085
   6 months 6.0 (4.0 to 8.0) 4.7 (3.2 to 6.2) 1.3 (-1.2 to 3.8) 0.312
  1. Mean differences between groups were obtained with analyses of covariance with the baseline value as a covariate. Means at three and six months are estimated marginal means. HADS = Hospital Anxiety and Depression Scale.